Does ERLOTINIB Cause Malignant neoplasm progression? 954 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 954 reports of Malignant neoplasm progression have been filed in association with ERLOTINIB (Erlotinib). This represents 4.3% of all adverse event reports for ERLOTINIB.
954
Reports of Malignant neoplasm progression with ERLOTINIB
4.3%
of all ERLOTINIB reports
494
Deaths
230
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ERLOTINIB?
Of the 954 reports, 494 (51.8%) resulted in death, 230 (24.1%) required hospitalization, and 21 (2.2%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ERLOTINIB. However, 954 reports have been filed with the FAERS database.
What Other Side Effects Does ERLOTINIB Cause?
Death (5,000)
Rash (4,648)
Diarrhoea (3,448)
Fatigue (1,548)
Nausea (1,366)
Drug ineffective (1,207)
Off label use (1,190)
Decreased appetite (998)
Dry skin (953)
Disease progression (910)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ERLOTINIB Alternatives Have Lower Malignant neoplasm progression Risk?
ERLOTINIB vs ERTAPENEM
ERLOTINIB vs ERTUGLIFLOZIN PIDOLATE
ERLOTINIB vs ERYTHROMYCIN
ERLOTINIB vs ERYTHROMYCIN ETHYLSUCCINATE
ERLOTINIB vs ERYTHROMYCIN LACTOBIONATE